A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

March 4, 2025

Study Completion Date

March 4, 2025

Conditions

Healthy VolunteersGeneralized Anxiety Disorder (GAD)Bipolar Disorder (BPD)

Interventions

DRUG

ABBV-932

Capsule; oral

DRUG

Placebo for ABBV-932

Capsule; oral

Trial Locations (3)

Acpru /Id# 255945, Grayslake

Collaborative Neuroscience Research CNS /ID# 260270, Los Alamitos

Hassman Research Institute Marlton Site /ID# 260271, Marlton